Macquarie Group’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-922,167
| Closed | -$118M | – | 1605 |
|
|
2025
Q2 | $118M | Sell |
922,167
-364,730
| -28% | -$37.9M | 0.15% | 182 |
|
|
2025
Q1 | $114M | Buy |
1,286,897
+27,921
| +2% | +$2.72M | 0.14% | 199 |
|
|
2024
Q4 | $110M | Sell |
1,258,976
-4,685
| -0.4% | -$429K | 0.13% | 217 |
|
|
2024
Q3 | $117M | Sell |
1,263,661
-48,406
| -4% | -$4.81M | 0.13% | 221 |
|
|
2024
Q2 | $141M | Buy |
1,312,067
+829
| +0.1% | +$83K | 0.16% | 165 |
|
|
2024
Q1 | $124M | Sell |
1,311,238
-257,709
| -16% | -$22.1M | 0.14% | 186 |
|
|
2023
Q4 | $145M | Sell |
1,568,947
-10,895
| -0.7% | -$706K | 0.17% | 157 |
|
|
2023
Q3 | $79.3M | Buy |
1,579,842
+61,756
| +4% | +$3.3M | 0.1% | 270 |
|
|
2023
Q2 | $95.9M | Buy |
1,518,086
+20,700
| +1% | +$1.13M | 0.11% | 243 |
|
|
2023
Q1 | $67.4M | Buy |
1,497,386
+186,636
| +14% | +$8.41M | 0.08% | 326 |
|
|
2022
Q4 | $57.4M | Buy |
1,310,750
+24,161
| +2% | +$1.16M | 0.07% | 399 |
|
|
2022
Q3 | $84.8M | Buy |
1,286,589
+11,700
| +0.9% | +$751K | 0.1% | 272 |
|
|
2022
Q2 | $64.4M | Buy |
1,274,889
+41,961
| +3% | +$2.46M | 0.07% | 370 |
|
|
2022
Q1 | $78.8K | Sell |
1,232,928
-43,834
| -3% | -$3.15M | 0.06% | 373 |
|
|
2021
Q4 | $137M | Sell |
1,276,762
-18,656
| -1% | -$1.95M | 0.11% | 237 |
|
|
2021
Q3 | $133M | Buy |
1,295,418
+134,967
| +12% | +$12.6M | 0.11% | 234 |
|
|
2021
Q2 | $102M | Buy |
1,160,451
+318,833
| +38% | +$29.2M | 0.08% | 297 |
|
|
2021
Q1 | $81.8M | Buy |
841,618
+7,415
| +0.9% | +$740K | 0.12% | 211 |
|
|
2020
Q4 | $93.6M | Buy |
834,203
+73,638
| +10% | +$7.76M | 0.14% | 166 |
|
|
2020
Q3 | $70.5M | Buy |
760,565
+563,027
| +285% | +$43.4M | 0.12% | 186 |
|
|
2020
Q2 | $15.4M | Buy |
197,538
+169,374
| +601% | +$11.5M | 0.03% | 533 |
|
|
2020
Q1 | $1.65M | Buy |
28,164
+15,666
| +125% | +$1.01M | ﹤0.01% | 968 |
|
|
2019
Q4 | $1M | Sell |
12,498
-105,060
| -89% | -$7.87M | ﹤0.01% | 1242 |
|
|
2019
Q3 | $8.64M | Buy |
+117,558
| New | +$10.2M | 0.01% | 634 |
|
Other funds holding BPMC
IA
HNB
Macquarie Group's BPMC Position: Q3 2025 in Review
Macquarie Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 922,167 shares — an estimated $118M sold.
Macquarie Group first reported a position in BPMC in Q3 2019 and held it in 24 quarters. The position peaked at $145M in Q4 2023. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Macquarie Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Macquarie Group sold 922,167 Blueprint Medicines shares in Q3 2025, an estimated $118M.
- Macquarie Group first reported a position in Blueprint Medicines in Q3 2019 and held it in 24 quarters.
- Macquarie Group's Blueprint Medicines position peaked at $145M in Q4 2023.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Macquarie Group's 13F filing for Q3 2025, filed 13 Nov 2025.